Osvaldo Ulises Garay
Research Subjects
Osvaldo Ulises Garay has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Alexander Lefevre
Affiliation Government, Access & Patient Affairs, Roche Diagnostics Belgium, Brussels, Belgium
1 shared publicationAnna-Maria Olziersky
Affiliation Roche Diagnostics International Ltd, Rotkreuz, Switzerland
1 shared publication- Anucha Apisarnthanarak
Thammasat University Hospital
1 shared publication - Camilla Porta
AdRes-Health Economics and Outcome Research, Turin, Italy
1 shared publication Cyrill Wolf
Roche Diagnostics (Schweiz) AG, Switzerland
1 shared publicationDamien Gruson
Affiliation Department of Clinical Biochemistry, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e343
Procalcitonin-guided antimicrobial stewardship for sepsis or lower respiratory tract infection in Thailand: a budget impact analysis
Objective: To estimate the budget and healthcare impact of using procalcitonin (PCT)-guided antimicrobial stewardship for sepsis or lower respiratory tract infection (LRTI) in Thailand. Design: Cost and clinical outcomes were modeled, comparing intervention with PCT-guided antimicrobial stewardship plus routine practice versus standard of care. The primary outcome was the annual budget impact. Secondary outcomes were the duration of antibiotic treatment and numbers of antibiotic-resistant and Clostridioides difficile cases per year. Sensitivity analyses assessed parameter uncertainty. Scenario analyses explored the budget impact of variations in local clinical practice. Setting: Hospitalized patients with suspected sepsis or with LRTI in Thailand. Intervention: PCT-guided antimicrobial stewardship plus routine practice. Results: The model predicted that PCT-guided antimicrobial stewardship versus standard of care for sepsis and LRTI, respectively, would result in 270.6 (95% CI: −413.9, −160.2) and 917.1 (95% CI: −1,092.3, −421.5) thousand fewer antibiotic treatment days; 1.1 (95% CI: −2.3, −.5) and 23.2 (95% CI: –45.6, −7.9) thousand fewer antibiotic-resistant cases; and 4.5 (95% CI: −11.8, −1.0) and 13.2 (95% CI: −35.4, −2.1) thousand fewer Clostridioides difficile cases. Total cost savings were estimated at 921 THB (95% CI: −2,132, −7) and 3,320 THB (95% CI: −6,617, −592), per patient per year, for sepsis and LRTI, respectively. In sensitivity analyses, the probability of cost savings was 98% for sepsis and 100% for LRTI. Scenario analyses indicated that greater cost savings could be achieved in some scenarios. Conclusions: PCT-guided antimicrobial stewardship for sepsis and LRTI could deliver economic benefits compared with current standard of care in Thailand.
- 21 October 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e343
Open AccessProcalcitonin-guided antimicrobial stewardship for sepsis or lower respiratory tract infection in Thailand: a budget impact analysis
Objective: To estimate the budget and healthcare impact of using procalcitonin (PCT)-guided antimicrobial stewardship for sepsis or lower respiratory tract infection (LRTI) in Thailand. Design: Cost and clinical outcomes were modeled, comparing intervention with PCT-guided antimicrobial stewardship plus routine practice versus standard of care. The primary outcome was the annual budget impact. Secondary outcomes were the duration of antibiotic treatment and numbers of antibiotic-resistant and Clostridioides difficile cases per year. Sensitivity analyses assessed parameter uncertainty. Scenario analyses explored the budget impact of variations in local clinical practice. Setting: Hospitalized patients with suspected sepsis or with LRTI in Thailand. Intervention: PCT-guided antimicrobial stewardship plus routine practice. Results: The model predicted that PCT-guided antimicrobial stewardship versus standard of care for sepsis and LRTI, respectively, would result in 270.6 (95% CI: −413.9, −160.2) and 917.1 (95% CI: −1,092.3, −421.5) thousand fewer antibiotic treatment days; 1.1 (95% CI: −2.3, −.5) and 23.2 (95% CI: –45.6, −7.9) thousand fewer antibiotic-resistant cases; and 4.5 (95% CI: −11.8, −1.0) and 13.2 (95% CI: −35.4, −2.1) thousand fewer Clostridioides difficile cases. Total cost savings were estimated at 921 THB (95% CI: −2,132, −7) and 3,320 THB (95% CI: −6,617, −592), per patient per year, for sepsis and LRTI, respectively. In sensitivity analyses, the probability of cost savings was 98% for sepsis and 100% for LRTI. Scenario analyses indicated that greater cost savings could be achieved in some scenarios. Conclusions: PCT-guided antimicrobial stewardship for sepsis and LRTI could deliver economic benefits compared with current standard of care in Thailand.
- Open Access
- 1 May 2026
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 156 (5) , 4469
Expanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis
BACKGROUND: European and Swiss guidelines recommend hepatocellular carcinoma surveillance of high-risk patients every 6 months using ultrasound (US), with/without α-fetoprotein (AFP). Other surveillance strategies are available, but evidence of their comparative cost-effectiveness is lacking. This study evaluated the cost-effectiveness of current hepatocellular carcinoma surveillance strategies in Switzerland, including the novel GAAD (gender [biological sex], age, α-fetoprotein, protein induced by vitamin K absence or antagonist-II [PIVKA-II]) serum-based algorithm in high-risk patients. METHODS: A micro-simulated Markov model estimated the cost-effectiveness of hepatocellular carcinoma surveillance strategies (no surveillance, US, US+AFP, GAAD) performed at 6-monthly intervals in a simulated cohort of 100,000 patients with compensated liver cirrhosis over a lifetime horizon. Performance parameters were sourced from published meta-analyses and multicentre study data. Epidemiological parameters were estimated based on literature identified during a previous systematic literature review. Similarly, utility parameters were sourced from published literature. Costs were sourced from TARMED, the Analysis List, the Swiss Federal Statistical Office, publicly available data and published literature. Primary outcomes were life years lived, quality-adjusted life years, and costs per patient and per cohort. The cost-effectiveness of each strategy was analysed through incremental cost-effectiveness ratios at a cost-effectiveness threshold of Swiss Franc (CHF) 100,000/quality-adjusted life year. RESULTS: Overall, the total costs and quality-adjusted life years per patient, respectively, were CHF 43,493.61 and 5.893 for no surveillance; CHF 48,702.79 and 6.018 for US; CHF 49,980.60 and 6.042 for US+AFP; and CHF 49,983.10 and 6.048 for GAAD. Compared with US+AFP and US alone, GAAD was cost-effective, with higher quality-adjusted life years and the highest rate of early-stage hepatocellular carcinoma detection (56%). Compared with no surveillance, incremental cost-effectiveness ratios for US, US+AFP and GAAD were considered to be cost-effective, ranging from CHF 41,509.01 to CHF 43,321.81. CONCLUSIONS: The current model indicates that hepatocellular carcinoma surveillance with any of these strategies was cost-effective in Switzerland. GAAD was nearly cost-neutral versus US+AFP, although these findings were dependent on the performance of GAAD and operator-dependent US combined with AFP. Compared with US alone, GAAD was the most cost-effective strategy. Further investigations are required to confirm these findings and to optimise hepatocellular carcinoma surveillance.
- 1 May 2026
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 156 (5) , 4469
Open AccessExpanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis
BACKGROUND: European and Swiss guidelines recommend hepatocellular carcinoma surveillance of high-risk patients every 6 months using ultrasound (US), with/without α-fetoprotein (AFP). Other surveillance strategies are available, but evidence of their comparative cost-effectiveness is lacking. This study evaluated the cost-effectiveness of current hepatocellular carcinoma surveillance strategies in Switzerland, including the novel GAAD (gender [biological sex], age, α-fetoprotein, protein induced by vitamin K absence or antagonist-II [PIVKA-II]) serum-based algorithm in high-risk patients. METHODS: A micro-simulated Markov model estimated the cost-effectiveness of hepatocellular carcinoma surveillance strategies (no surveillance, US, US+AFP, GAAD) performed at 6-monthly intervals in a simulated cohort of 100,000 patients with compensated liver cirrhosis over a lifetime horizon. Performance parameters were sourced from published meta-analyses and multicentre study data. Epidemiological parameters were estimated based on literature identified during a previous systematic literature review. Similarly, utility parameters were sourced from published literature. Costs were sourced from TARMED, the Analysis List, the Swiss Federal Statistical Office, publicly available data and published literature. Primary outcomes were life years lived, quality-adjusted life years, and costs per patient and per cohort. The cost-effectiveness of each strategy was analysed through incremental cost-effectiveness ratios at a cost-effectiveness threshold of Swiss Franc (CHF) 100,000/quality-adjusted life year. RESULTS: Overall, the total costs and quality-adjusted life years per patient, respectively, were CHF 43,493.61 and 5.893 for no surveillance; CHF 48,702.79 and 6.018 for US; CHF 49,980.60 and 6.042 for US+AFP; and CHF 49,983.10 and 6.048 for GAAD. Compared with US+AFP and US alone, GAAD was cost-effective, with higher quality-adjusted life years and the highest rate of early-stage hepatocellular carcinoma detection (56%). Compared with no surveillance, incremental cost-effectiveness ratios for US, US+AFP and GAAD were considered to be cost-effective, ranging from CHF 41,509.01 to CHF 43,321.81. CONCLUSIONS: The current model indicates that hepatocellular carcinoma surveillance with any of these strategies was cost-effective in Switzerland. GAAD was nearly cost-neutral versus US+AFP, although these findings were dependent on the performance of GAAD and operator-dependent US combined with AFP. Compared with US alone, GAAD was the most cost-effective strategy. Further investigations are required to confirm these findings and to optimise hepatocellular carcinoma surveillance.
- Open Access
- 17 February 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 406-420
Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data
Early detection of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis (CC) is critical for improving prognosis. The GAAD algorithm (gender [biological sex], age, alpha-fetoprotein [AFP], protein induced by vitamin K absence-II [PIVKA-II]) demonstrated good performance for the detection of early-stage HCC. This study aimed to assess the cost-effectiveness of the GAAD algorithm for HCC surveillance in patients with CC in Italy, from the Italian Health Service perspective. A probabilistic micro-simulation Markov model was adapted to the Italian context to estimate lifetime clinical outcomes and costs of CC patients undergoing bi-annual surveillance with ultrasound (US), US+AFP, GAAD, and US+GAAD. Clinical inputs and utility values were derived from Italian real-world data and published literature. Direct healthcare costs were collected from Italian sources. Costs and outcomes were discounted at an annual 3% rate. Sensitivity analyses were conducted to evaluate the uncertainties in input parameters. In a simulated cohort of 100,000 CC patients, QALYs and costs per patient were 6.53 and €35,524 for US, 6.56 and €35,825 for US+AFP, 6.57 and €35,423 for GAAD, and 6.58 and €35,939 for US+GAAD. Compared to US and US+AFP, GAAD was dominant, while US+GAAD was cost-effective (ICUR of €9,482 and €10,951 per QALY gained, respectively). At a willingness-to-pay threshold of €30,000, GAAD was the most cost-effective strategy. Sensitivity analyses confirmed the robustness of results. Assumptions were required to estimate the diagnostic performance of US+GAAD, given the absence of prospective validation data. Some clinical parameters were derived from non-Italian sources, which may limit generalizability. GAAD, alone or combined with US, is a cost-effective strategy for HCC surveillance in CC patients in Italy, improving the detection of early-stage disease. Better performance data for US+GAAD is needed to confirm results.
- 17 February 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 406-420
Open AccessCost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data
Early detection of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis (CC) is critical for improving prognosis. The GAAD algorithm (gender [biological sex], age, alpha-fetoprotein [AFP], protein induced by vitamin K absence-II [PIVKA-II]) demonstrated good performance for the detection of early-stage HCC. This study aimed to assess the cost-effectiveness of the GAAD algorithm for HCC surveillance in patients with CC in Italy, from the Italian Health Service perspective. A probabilistic micro-simulation Markov model was adapted to the Italian context to estimate lifetime clinical outcomes and costs of CC patients undergoing bi-annual surveillance with ultrasound (US), US+AFP, GAAD, and US+GAAD. Clinical inputs and utility values were derived from Italian real-world data and published literature. Direct healthcare costs were collected from Italian sources. Costs and outcomes were discounted at an annual 3% rate. Sensitivity analyses were conducted to evaluate the uncertainties in input parameters. In a simulated cohort of 100,000 CC patients, QALYs and costs per patient were 6.53 and €35,524 for US, 6.56 and €35,825 for US+AFP, 6.57 and €35,423 for GAAD, and 6.58 and €35,939 for US+GAAD. Compared to US and US+AFP, GAAD was dominant, while US+GAAD was cost-effective (ICUR of €9,482 and €10,951 per QALY gained, respectively). At a willingness-to-pay threshold of €30,000, GAAD was the most cost-effective strategy. Sensitivity analyses confirmed the robustness of results. Assumptions were required to estimate the diagnostic performance of US+GAAD, given the absence of prospective validation data. Some clinical parameters were derived from non-Italian sources, which may limit generalizability. GAAD, alone or combined with US, is a cost-effective strategy for HCC surveillance in CC patients in Italy, improving the detection of early-stage disease. Better performance data for US+GAAD is needed to confirm results.
- Open Access
- 17 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0326162
Economic impact of the Elecsys anti-Müllerian hormone Plus immunoassay for anti-Müllerian hormone testing as part of polycystic ovary syndrome assessment in the United Kingdom
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women. Current international PCOS assessment and management guidelines recommend anti-Müllerian hormone (AMH) as an alternative to transvaginal ultrasound for assessing polycystic ovarian morphology, which is one of three criteria for diagnosing PCOS. This study assessed the economic impact of using the Elecsys® AMH Plus immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) for AMH testing in the United Kingdom health system to assess women with signs and symptoms of PCOS. A decision tree model estimated the costs and health outcomes of using the Elecsys AMH Plus immunoassay to determine polycystic ovarian morphology as part of PCOS assessment in a simulated cohort of women aged 25–45 years who were exposed to different diagnosis pathways. The comparator scenario was the standard of care, where transvaginal ultrasound was used for assessment. Base-case results indicated that the Elecsys AMH Plus immunoassay could lead to cost savings of £284,029 per year on the total cost of PCOS diagnosis (1.4% reduction vs. transvaginal ultrasound), in addition to savings on managing secondary comorbidities, such as type 2 diabetes and stroke care. Cost savings with the Elecsys AMH Plus immunoassay were observed in all scenarios versus using transvaginal ultrasound, including scenarios with various referral rates to specialists and dropout rates from the diagnosis pathway, and low adherence to lifestyle recommendations. With the known current delays in the United Kingdom for diagnosis of PCOS, implementing the Elecsys AMH Plus immunoassay for AMH testing may not only provide cost benefits, but also reduce waiting times for diagnosis and treatment, improving patient health outcomes.
- 17 June 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (6) , e0326162
Open AccessEconomic impact of the Elecsys anti-Müllerian hormone Plus immunoassay for anti-Müllerian hormone testing as part of polycystic ovary syndrome assessment in the United Kingdom
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women. Current international PCOS assessment and management guidelines recommend anti-Müllerian hormone (AMH) as an alternative to transvaginal ultrasound for assessing polycystic ovarian morphology, which is one of three criteria for diagnosing PCOS. This study assessed the economic impact of using the Elecsys® AMH Plus immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) for AMH testing in the United Kingdom health system to assess women with signs and symptoms of PCOS. A decision tree model estimated the costs and health outcomes of using the Elecsys AMH Plus immunoassay to determine polycystic ovarian morphology as part of PCOS assessment in a simulated cohort of women aged 25–45 years who were exposed to different diagnosis pathways. The comparator scenario was the standard of care, where transvaginal ultrasound was used for assessment. Base-case results indicated that the Elecsys AMH Plus immunoassay could lead to cost savings of £284,029 per year on the total cost of PCOS diagnosis (1.4% reduction vs. transvaginal ultrasound), in addition to savings on managing secondary comorbidities, such as type 2 diabetes and stroke care. Cost savings with the Elecsys AMH Plus immunoassay were observed in all scenarios versus using transvaginal ultrasound, including scenarios with various referral rates to specialists and dropout rates from the diagnosis pathway, and low adherence to lifestyle recommendations. With the known current delays in the United Kingdom for diagnosis of PCOS, implementing the Elecsys AMH Plus immunoassay for AMH testing may not only provide cost benefits, but also reduce waiting times for diagnosis and treatment, improving patient health outcomes.
- Open Access
- 25 September 2024
- Published by Federacion Colombiana de Obstetricia y Ginecologia in Revista Colombiana de Obstetricia Y Ginecologia
- Vol. 75 (3)
Análisis económico del cociente de preeclampsia sFlt- 1/PlGF comparado con el estándar de atención en Uruguay
Objetivos: la preeclampsia (PE) es un trastorno hipertensivo del embarazo que puede causar complicaciones graves y resultados adversos maternos y fetales. El objetivo del estudio fue estimar el impacto económico de la incorporación del cociente sFlt-1/PlGF (factor tirosinkinasa -1 soluble tipo fms / Placenta Growth Factor – Factor de Crecimiento Placentario) al sistema de salud uruguayo. Materiales y métodos: se utilizó un árbol de decisión para estimar, en una cohorte hipotética de mujeres con sospecha de PE, el impacto económico anual incluidos los costos relevantes asociados con el diagnóstico, el seguimiento y el tratamiento de la presentación inicial de la PE clínicamente sospechada hasta el parto. Se analizaron los costos anuales para un escenario estándar de atención y un escenario que incluye el cociente sFlt-1/PlGF para PE. Se realizaron diversos análisis de sensibilidad determinísticos y probabilísticos. Resultados: el modelo económico estimó que el uso del cociente sFlt-1/PlGF permitiría al sistema de salud uruguayo ahorrar 95.432.678 pesos uruguayos (2.320.269 dólares) anualmente: una reducción del 5 % en comparación con el estándar de atención, principalmente como resultado de la reducción de las hospitalizaciones de mujeres con sospecha de PE. El cálculo del impacto económico estimó un ahorro neto anual de aproximadamente 10.602 pesos uruguayos (258 dólares) por paciente. Conclusiones: la introducción del cociente sFlt-1/PlGF en el sistema de salud uruguayo probablemente genere ahorros debido a la optimización del manejo de las hospitalizaciones de mujeres con sospecha de PE, aunque la posibilidad de obtener ahorros dependerá principalmente de la tasa actual de hospitalización de estas (la eficiencia del manejo de los embarazos de alto riesgo de PE), y de los días de internación de las mujeres hospitalizadas.
- 25 September 2024
- Published by Federacion Colombiana de Obstetricia y Ginecologia in Revista Colombiana de Obstetricia Y Ginecologia
- Vol. 75 (3)
Open AccessAnálisis económico del cociente de preeclampsia sFlt- 1/PlGF comparado con el estándar de atención en Uruguay
Objetivos: la preeclampsia (PE) es un trastorno hipertensivo del embarazo que puede causar complicaciones graves y resultados adversos maternos y fetales. El objetivo del estudio fue estimar el impacto económico de la incorporación del cociente sFlt-1/PlGF (factor tirosinkinasa -1 soluble tipo fms / Placenta Growth Factor – Factor de Crecimiento Placentario) al sistema de salud uruguayo. Materiales y métodos: se utilizó un árbol de decisión para estimar, en una cohorte hipotética de mujeres con sospecha de PE, el impacto económico anual incluidos los costos relevantes asociados con el diagnóstico, el seguimiento y el tratamiento de la presentación inicial de la PE clínicamente sospechada hasta el parto. Se analizaron los costos anuales para un escenario estándar de atención y un escenario que incluye el cociente sFlt-1/PlGF para PE. Se realizaron diversos análisis de sensibilidad determinísticos y probabilísticos. Resultados: el modelo económico estimó que el uso del cociente sFlt-1/PlGF permitiría al sistema de salud uruguayo ahorrar 95.432.678 pesos uruguayos (2.320.269 dólares) anualmente: una reducción del 5 % en comparación con el estándar de atención, principalmente como resultado de la reducción de las hospitalizaciones de mujeres con sospecha de PE. El cálculo del impacto económico estimó un ahorro neto anual de aproximadamente 10.602 pesos uruguayos (258 dólares) por paciente. Conclusiones: la introducción del cociente sFlt-1/PlGF en el sistema de salud uruguayo probablemente genere ahorros debido a la optimización del manejo de las hospitalizaciones de mujeres con sospecha de PE, aunque la posibilidad de obtener ahorros dependerá principalmente de la tasa actual de hospitalización de estas (la eficiencia del manejo de los embarazos de alto riesgo de PE), y de los días de internación de las mujeres hospitalizadas.
- Open Access
- 9 August 2024
- Published by Elsevier in Value in Health
- Vol. 27 (12) , 1698-1709
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom
- 9 August 2024
- Published by Elsevier in Value in Health
- Vol. 27 (12) , 1698-1709
Open AccessCost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom
- Open Access
- 30 October 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (10) , e0293544
The budget impact of procalcitonin-guided antibiotic stewardship compared to standard of care for patients with suspected sepsis admitted to the intensive care unit in Belgium
In Belgium, antibiotic resistance leads to approximately 530 deaths with a €24 million financial burden annually. This study estimated the impact of procalcitonin-guided antibiotic stewardship programs to reduce antibiotic consumption versus standard of care in patients with suspected sepsis. A decision analytic tree modelled health and budget outcomes of procalcitonin-guided antibiotic stewardship programs for patients admitted to the intensive care unit (ICU). A literature search, a survey with local clinical experts, and national database searches were conducted to obtain model input parameters. The main outcomes were total budget impact per patient, reduction in number of antibiotic resistance cases, and cost per antibiotic day avoided. To evaluate the impact of parameter uncertainty on the source data, a deterministic sensitivity analysis was performed. A scenario analysis was conducted to investigate budget impact when including parameters for reduction in length of ICU stay and mechanical ventilation duration, in addition to base-case parameters. Based on model predictions, procalcitonin-guided antibiotic stewardship programs could reduce the number of antibiotic days by 66,868, resulting in €1.98 million savings towards antibiotic treatment in current clinical practice. Antibiotic resistance cases could decrease by 7.7% (6.1% vs 9.2%) in the procalcitonin-guided setting compared with standard of care. The base-case budget impact suggests an investment of €1.90 per patient. The sensitivity analysis showed uncertainty, as the main drivers can alter potential cost savings. The scenario analysis indicated a saving of €1,405 per patient, with a reduction of 1.5 days in the ICU (14.8 days vs 12.8 days), and a reduction of 22.7% (18.1–27.2%) in mechanical ventilation duration. The associated sensitivity analysis was shown to be robust in all parameters. Procalcitonin-guided antibiotic stewardship programs are associated with clinical benefits that positively influence antimicrobial resistance in Belgium. A small investment per patient to implement procalcitonin testing may lead to considerable cost savings.
- 30 October 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (10) , e0293544
Open AccessThe budget impact of procalcitonin-guided antibiotic stewardship compared to standard of care for patients with suspected sepsis admitted to the intensive care unit in Belgium
In Belgium, antibiotic resistance leads to approximately 530 deaths with a €24 million financial burden annually. This study estimated the impact of procalcitonin-guided antibiotic stewardship programs to reduce antibiotic consumption versus standard of care in patients with suspected sepsis. A decision analytic tree modelled health and budget outcomes of procalcitonin-guided antibiotic stewardship programs for patients admitted to the intensive care unit (ICU). A literature search, a survey with local clinical experts, and national database searches were conducted to obtain model input parameters. The main outcomes were total budget impact per patient, reduction in number of antibiotic resistance cases, and cost per antibiotic day avoided. To evaluate the impact of parameter uncertainty on the source data, a deterministic sensitivity analysis was performed. A scenario analysis was conducted to investigate budget impact when including parameters for reduction in length of ICU stay and mechanical ventilation duration, in addition to base-case parameters. Based on model predictions, procalcitonin-guided antibiotic stewardship programs could reduce the number of antibiotic days by 66,868, resulting in €1.98 million savings towards antibiotic treatment in current clinical practice. Antibiotic resistance cases could decrease by 7.7% (6.1% vs 9.2%) in the procalcitonin-guided setting compared with standard of care. The base-case budget impact suggests an investment of €1.90 per patient. The sensitivity analysis showed uncertainty, as the main drivers can alter potential cost savings. The scenario analysis indicated a saving of €1,405 per patient, with a reduction of 1.5 days in the ICU (14.8 days vs 12.8 days), and a reduction of 22.7% (18.1–27.2%) in mechanical ventilation duration. The associated sensitivity analysis was shown to be robust in all parameters. Procalcitonin-guided antibiotic stewardship programs are associated with clinical benefits that positively influence antimicrobial resistance in Belgium. A small investment per patient to implement procalcitonin testing may lead to considerable cost savings.
- Open Access
- 4 November 2022
- Published by Elsevier in Value in Health Regional Issues
- Vol. 34, 1-8
Economic Impact Analysis of Incorporation of Elecsys sFlt-1/PlGF Ratio Into Routine Practice for the Diagnosis and Follow-Up of Pregnant Women With Suspected Preeclampsia in Argentina
- 4 November 2022
- Published by Elsevier in Value in Health Regional Issues
- Vol. 34, 1-8
Open AccessEconomic Impact Analysis of Incorporation of Elecsys sFlt-1/PlGF Ratio Into Routine Practice for the Diagnosis and Follow-Up of Pregnant Women With Suspected Preeclampsia in Argentina
- 1 December 2021
- Published by Elsevier in Value in Health Regional Issues
- Vol. 26, 160-168
Cost-Effectiveness and Budget Impact Analysis of Primary Screening With Human Papillomavirus Test With Genotyping in Argentina
- 1 December 2021
- Published by Elsevier in Value in Health Regional Issues
- Vol. 26, 160-168
Cost-Effectiveness and Budget Impact Analysis of Primary Screening With Human Papillomavirus Test With Genotyping in Argentina
- Open Access
- 30 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0250711
Budget impact analysis of using procalcitonin to optimize antimicrobial treatment for patients with suspected sepsis in the intensive care unit and hospitalized lower respiratory tract infections in Argentina
Background: Inappropriate antibiotic use represents a major global threat. Sepsis and bacterial lower respiratory tract infections (LRTIs) have been linked to antimicrobial resistance, carrying important consequences for patients and health systems. Procalcitonin-guided algorithms may represent helpful tools to reduce antibiotic overuse but the financial burden is unclear. The aim of this study was to estimate the healthcare and budget impact in Argentina of using procalcitonin-guided algorithms to guide antibiotic prescription.Methods: A decision tree was used to model health and cost outcomes for the Argentinean health system, over a one-year duration. Patients with suspected sepsis in the intensive care unit and hospitalized patients with LRTI were included. Model parameters were obtained from a focused, non-systematic, local and international bibliographic search, and validated by a panel of local experts. Deterministic and probabilistic sensitivity analyses were performed to analyze the uncertainty of parameters.Results: The model predicted that using procalcitonin-guided algorithms would result in 734.5 [95% confidence interval (CI): 1,105.2;438.8] thousand fewer antibiotic treatment days, 7.9 [95% CI: 18.5;8.5] thousand antibiotic-resistant cases avoided, and 5.1 [95% CI: 6.7;4.2] thousand fewerClostridioides difficilecases. In total, this would save $422.4 US dollars (USD) [95% CI: $935;$267] per patient per year, meaning cost savings of $83.0 [95% CI: $183.6;$57.7] million USD for the entire health system and $0.4 [95% CI: $0.9;$0.3] million USD for a healthcare provider with 1,000 cases per year of sepsis and LRTI patients. The sensitivity analysis showed that the probability of cost-saving for the sepsis patient group was lower than for the LRTI patient group (85% vs. 100%).Conclusions: Healthcare and financial benefits can be obtained by implementing procalcitonin-guided algorithms in Argentina. Although we found results to be robust on an aggregate level, some caution must be used when focusing only on sepsis patients in the intensive care unit.
- 30 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0250711
Open AccessBudget impact analysis of using procalcitonin to optimize antimicrobial treatment for patients with suspected sepsis in the intensive care unit and hospitalized lower respiratory tract infections in Argentina
Background: Inappropriate antibiotic use represents a major global threat. Sepsis and bacterial lower respiratory tract infections (LRTIs) have been linked to antimicrobial resistance, carrying important consequences for patients and health systems. Procalcitonin-guided algorithms may represent helpful tools to reduce antibiotic overuse but the financial burden is unclear. The aim of this study was to estimate the healthcare and budget impact in Argentina of using procalcitonin-guided algorithms to guide antibiotic prescription.Methods: A decision tree was used to model health and cost outcomes for the Argentinean health system, over a one-year duration. Patients with suspected sepsis in the intensive care unit and hospitalized patients with LRTI were included. Model parameters were obtained from a focused, non-systematic, local and international bibliographic search, and validated by a panel of local experts. Deterministic and probabilistic sensitivity analyses were performed to analyze the uncertainty of parameters.Results: The model predicted that using procalcitonin-guided algorithms would result in 734.5 [95% confidence interval (CI): 1,105.2;438.8] thousand fewer antibiotic treatment days, 7.9 [95% CI: 18.5;8.5] thousand antibiotic-resistant cases avoided, and 5.1 [95% CI: 6.7;4.2] thousand fewerClostridioides difficilecases. In total, this would save $422.4 US dollars (USD) [95% CI: $935;$267] per patient per year, meaning cost savings of $83.0 [95% CI: $183.6;$57.7] million USD for the entire health system and $0.4 [95% CI: $0.9;$0.3] million USD for a healthcare provider with 1,000 cases per year of sepsis and LRTI patients. The sensitivity analysis showed that the probability of cost-saving for the sepsis patient group was lower than for the LRTI patient group (85% vs. 100%).Conclusions: Healthcare and financial benefits can be obtained by implementing procalcitonin-guided algorithms in Argentina. Although we found results to be robust on an aggregate level, some caution must be used when focusing only on sepsis patients in the intensive care unit.